Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Condylomata acuminata; Human papillomavirus infections; Penile cancer
- Focus Pharmacodynamics; Registrational
- Sponsors Shanghai Bovax Biotechnology
- 23 Feb 2022 Planned number of patients changed from 1350 to 1348.
- 23 Feb 2022 Status changed from not yet recruiting to recruiting.
- 06 Sep 2021 New trial record